PT - JOURNAL ARTICLE AU - María Gallardo-Gómez AU - Lara Costas-Ríos AU - Carlos A. Garcia-Prieto AU - Lara Álvarez-Rodríguez AU - Luis Bujanda AU - Maialen Barrero AU - Antoni Castells AU - Francesc Balaguer AU - Rodrigo Jover AU - Manel Esteller AU - Antoni Tardío Baiges AU - Joaquín González-Carreró Fojón AU - Joaquín Cubiella AU - Loretta De Chiara TI - Serum DNA methylome of the colorectal cancer serrated pathway AID - 10.1101/2022.03.25.22272961 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.25.22272961 4099 - http://medrxiv.org/content/early/2022/03/31/2022.03.25.22272961.short 4100 - http://medrxiv.org/content/early/2022/03/31/2022.03.25.22272961.full AB - Objective The clinical relevance of the serrated pathway of colorectal carcinogenesis is evident but the screening of serrated lesions remains challenging. We aimed to characterize the serum methylome of the serrated pathway, and to evaluate circulating cell-free DNA (cfDNA) methylation as a source of biomarkers for the non-invasive screening and diagnosis of serrated lesions.Design We collected serum samples from individuals with serrated adenocarcinoma (SAC), traditional serrated adenomas, sessile serrated lesions, hyperplastic polyps and with no colorectal findings. First, epigenome-wide methylation was quantified in cfDNA pooled samples with the MethylationEPIC array. Then, methylation profiles were compared to tissue and serum cfDNA datasets. Finally, biomarker utility of serum cfDNA methylation was evaluated.Results We identified a differential methylation profile that can distinguish high-risk serrated lesions from the absence of serrated neoplasia, showing concordance with tissue methylation from SAC and sessile serrated lesions (external datasets). We report that the methylation profiles in serum cfDNA are pathway-specific, clearly separating serrated lesions from conventional adenomas. Among the differentially methylated regions (DMR) we report, the combination of two DMRs within the genes NINJ2 and ERICH1 discriminated high-risk serrated lesions and SAC with 91.4% sensitivity and 64.4% specificity, while methylation from a DMR within ZNF718 reported 100% sensitivity for the detection of SAC at 96% specificity.Conclusion This is the only study available to date exploring the serum methylome of serrated lesions. We have identified a differential methylation profile in serum specific to the serrated pathway. The serum methylome may serve as a source of non-invasive biomarkers for screening and detection of high-risk serrated lesions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work received funding from Plan Nacional I +D +I 2015-2018 (Accion Estrategica en Salud) Instituto de Salud Carlos III (Spain)-FEDER (PI15/02007), 'Fundacion Cientifica de la Asociacion Espanola contra el Cancer' (GCB13131592CAST), and support from Centro Singular de Investigacion de Galicia (Conselleria de Cultura, Educaciin e Ordenacion Universitaria) (ED431G/02, Xunta de Galicia and FEDER-European Union). Maria Gallardo-Gomez was supported by a predoctoral fellowship from Ministerio de Educacion, Cultura y Deporte (Spanish Government) (FPU15/02350).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all patients with approval by the Ethics Committee for Clinical Research of Galicia (2018/008). The study was conducted according to the clinical and ethical principles of the Spanish Government and the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Infinium MethylationEPIC data from all the pooled samples generated and analyzed during this study have been deposited in the NCBI Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo) and are accessible through GEO Series accession number GSE199173. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE199173 AAadvanced adenomaAUCarea under the curvecfDNAcirculating cell-free DNACRCcolorectal cancerCGICpG islandDMRdifferentially methylated regionDMPdifferentially methylated positionFDRfalse discovery rateFITfecal immunochemical testFWERfamily-wise error rateHPhyperplastic polypHR-HPhigh-risk hyperplastic polypHR-SLhigh-risk serrated lesionHR-SPhigh-risk serrated polypMS-qPCRmethylation-specific quantitative PCRNAAnon-advanced adenomasNCFno colorectal findingsNMPnormalized methylation percentageNSNno serrated neoplasiaRMPraw methylation percentageROCReceiver-operating characteristicSACserrated adenocarcinomaSSLsessile serrated lesionSPserrated polypTSAtraditional serrated adenoma.